Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

SCCHN

Bristol-Myers Squibb (BMS) building

BMS pulls ahead of Merck in quarterly PD-1 inhibitor sales

Supports analysts prediction BMS' Opdivo will become market leader

Bristol-Myers Squibb (BMS) building

First data backs efficacy of BMS’ novel HIV drug

Could provide new treatment for those resistant to antiretroviral therapy

Bristol-Myers Squibb (BMS) building

BMS gets OK for broader Opdivo use in lung cancer

US regulator'sdecision allows firm to edge in front of Merck & Co's Keytruda

Bristol-Myers Squibb (BMS) building

Opdivo a breakthrough in kidney cancer, says FDA

BMSmoves closer to US approval of its checkpoint inhibitor cancer immunotherapy

Celgene building

Myeloma market set to be $9bn by 2021

New research shows it will pushed by a growing prevalence of the disease

- PMLiVE

FDA grants priority review for new Keytruda licence

Merck’s PD-1 drug being assessed for first-line melanoma patients

- PMLiVE

Novartis licenses cancer support drug from Aveo Oncology

Swiss firm buys into drug to alleviate a wasting syndrome that is seen in chronic patients

Roche Basel Switzerland

Roche’s PD-L1 drug shrinks lung tumours

Drug has already showed success in treating certain bladder cancer patients

- PMLiVE

BMS launches Opdivo for lung cancer in UK

Drug to be called ‘Nivolumab BMS’ in the country

- PMLiVE

AZ signs two more deals in cancer immunotherapy

Anglo-Swedish firm pens partnerships with Heptares and Mirati Therapeutics

Bristol-Myers Squibb (BMS) building

BMS signs Opdivo combination pact with Kyowa Hakko Kirin 

Rounds off a week of deals in the immunotherapy space for big pharma

- PMLiVE

Access to new hep C treatments put under the spotlight

NICE plans to restrict use of BMS’ Daklinza follow funding delay for Gilead's Sovaldi

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links